Skip to main content

Table 8 NMBA treatment (defined by > 3 days within 48 h from commencement of mechanical ventilation) vs controls on 90-day in-hospital mortality

From: Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

 

Propensity score-matched cohort

(N = 324)

90-day mortality from ICU admission

Control

(N = 162)

NMBA treatment

(N = 162)

Total

(N = 362)

Survived

130 (80.3%)

81 (50.0%)

211 (65.1%)

Died

32 (19.8%)

81 (50.0%)

113 (34.9%)

Total

162

162

324

  1. Prior to propensity score matching, neuromuscular blocking agent (NMBA) treatment, defined as more than 3 days of continuous use of NMBAs, within 48 h from commencement of invasive mechanical ventilation, was associated with 90-day mortality (unadjusted Cox regression; HR 2.57, 95% CI 2.02, 2.71, p < 0.001). After propensity score matching, 372 patients who received NMBA treatment were matched with 372 controls (using replacement). Using the propensity score-matched cohort and adjusting for covariates as per Table 4, NMBA therapy was associated with 90-day mortality (adjusted HR 1.73, 95% CI 1.27, 2.37, p = 0.001)